<DOC>
	<DOCNO>NCT00999401</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) recommend phase II dose sapacitabine seliciclib administer sequentially concomitantly . The secondary objective evaluate antitumor activity sequential concomitant treatment explore pharmacodynamic effect treatment skin peripheral blood mononuclear cell .</brief_summary>
	<brief_title>A Study Oral Sapacitabine Oral Seliciclib Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Roscovitine</mesh_term>
	<criteria>Incurable advance solid tumor longer respond conventional therapy effective therapy exist ; RD Part 1 , extension cohort 20 patient metastatic breast cancer know BRCA mutation carrier enrol . Age 18 year old ECOG 02 Life expectancy â‰¥ 3 month Evaluable disease Adequate bone marrow function Adequate renal function Adequate liver function At least 3 week prior systemic treatment include investigational anticancer therapy , radiation therapy ; recover prior toxicity Able swallow capsule At least 3 week major surgery Agree practice effective contraception Ability understand willingness sign inform consent form Previously untreated CNS metastasis progressive CNS metastasis Currently receive radiotherapy , biological therapy , investigational agent Uncontrolled intercurrent illness include Pregnant lactating woman Known HIVpositive A history active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>